Phen’X Technologies has sold a majority stake to Ciclad
The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.
Founded in 2011, Phen’X Technologies is specialized in medical subcontracting of implants and instruments for dental, maxillofacial and orthopedic applications. With two production sites in France and Portugal, the company manufactures a wide range of components to support surgeons in dental implantology, facial remodeling and orthopedics. The firm also assists its clients in industrialization projects, from the realization of 3D plans and prototypes to the machining of mass-produced parts.
Ciclad is a long-standing, independent private equity investor supporting the growth of small and mid-sized companies in France and abroad. Established in 1988, Ciclad has invested alongside more than 180 executives and management teams. It is involved in buy-outs and capital strengthening, particularly complex transactions such as spin-offs and carveouts, in contexts of strong development – organic growth and build-up – and turnarounds.
Oaklins’ team in France acted as the exclusive financial advisor to the shareholders of Phen’X Technologies in this LBO.
Contáctese con el equipo de la transacción
Transacciones relacionadas
Sunlight Group has acquired a 51% stake in Lehmann Marine GmbH
Through its acquisition of a 51% stake in Lehmann Marine GmbH, Sunlight Group continues to strengthen its position in the growing energy solutions market, while expanding its portfolio of innovative technologies. With over 30 years of expertise in producing lead-acid and lithium-ion batteries, Sunlight Group has established itself as a leader in advanced battery technology.
Conozca másDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Conozca másXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Conozca más